Article
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Clinical pharmacology and therapeutics - 1 Dec 2025
Eadon Michael T, Hein David W, Andersen Michael A, Chapman Arlene B, Cooper-DeHoff Rhonda M, Desta Zeruesenay, Duarte Julio D, Elchynski Amanda L, Gaedigk Andrea, Karol Seth E, Limdi Nita A, Lteif Christelle, Sosinski Laura, Zubiaur Pablo, Whirl-Carrillo Michelle, Klein Teri E, Caudle Kelly E, Donnelly Roseann S, Agúndez José A G
Abstract excerpt
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N-acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as "slow acetylators") are predicted to have increased plasma hydralazine concentrations compared with NAT2 rapid and intermediate metabolizers (historically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.